Navigation Links
WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
Date:8/22/2008

SHANGHAI, China, Aug. 22 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has promoted Dr. Rujian Ma to Vice President of Synthetic Chemistry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Ma will report directly to Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

"I am very delighted to promote Dr. Ma to this new leadership position. Dr. Ma's depth of synthetic chemistry experience and his commitment and coaching capabilities of our young scientists undoubtedly will further accelerate the development of our core synthetic chemistry division. His new assignment will also help us continually improve our service quality and productivity and to serve our customers better." commented Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

Dr. Ma received his Ph.D. in Organic Chemistry from the University of Tokushima, Japan and joined in WuXi in March 2001.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
2. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
3. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
4. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
5. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
6. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
7. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
8. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
9. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
10. WuXi PharmaTech Announces First Quarter 2008 Results
11. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2019)... (PRWEB) , ... September 30, 2019 , ... ... materials science newsletter from Rigaku Corporation , is now available online on ... to X-ray based materials science, including X-ray diffraction, fluorescence and imaging, and presents ...
(Date:9/24/2019)... (PRWEB) , ... September 24, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... a clinical-stage biopharmaceutical company focused on the development of therapies to treat ...
(Date:9/24/2019)... ... , ... In the past three years, the National Science Foundation (NSF) has ... School of Mines & Technology that expands human understanding of the microbial world. ... slimy and yet strong layer which is commonly known as a biofilm. , The ...
(Date:9/17/2019)... ... 2019 , ... Tucker, a Labrador retriever, was just a puppy when he ... and lame on his right hip and elbow. At one year of age, Tucker ... case the vet had seen.” He was prescribed pain medications, both oral and injectable, ...
Breaking Biology Technology:
(Date:10/3/2019)... ... October 02, 2019 , ... Personalized Stem Cells, ... patient in an FDA approved clinical trial for stem cell treatment of knee ... formation of the company as a subsidiary of VetStem Biopharma. , PSC CEO, Michael ...
(Date:9/30/2019)... ... September 30, 2019 , ... ... mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent ... product formats (patent number AU 2015259373). This new patent adds intellectual property ...
(Date:9/25/2019)... ... , ... Deep Science Ventures (DSV), a new paradigm for applied ... of cancer research. , Deep Science Ventures was founded to create a better method ... from the start, both at the industry and biological level. , Through their ...
Breaking Biology News(10 mins):